Internal medicine

Pathology

Placebo

Disease

Dementia

Gastroenterology

Psychology

Alternative medicine

Mini–Mental State Examination

Alzheimer's disease

Medicine

New England Journal of Medicine

Alzheimer's disease is characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles. The humanized monoclonal antibody solanezumab was designed to increase the clearance from the brain of soluble Aβ, peptides that may lead to toxic effects in the synapses and precede the deposition of fibrillary amyloid.

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease